Andrew S Judd

USPTO Granted Patents = 21 (Patent Applications = 52)

CIPO Patents = 1 (Patent Applications = 22)

EPO Patents = 9 (Patent Applications = 27)

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 49(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

patents

Years Active: 2006-2024

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11964990 - 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors (2024-04-23),

2. 11786519 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2023-10-17),

3. 10676485 - Macrocyclic MCL-1 inhibitors and methods of use (2020-06-09),

4. 10640563 - Anti-B7-H3 antibodies and antibody drug conjugates (2020-05-05),

5. 10081628 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2018-09-25),

6. 9877958 - Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases (2018-01-30),

7. 9844547 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2017-12-19),

8. 9266877 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-02-23),

9. 9227963 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-01-05),

10. 9051327 - Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases (2015-06-09),

11. 8940737 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2015-01-27),

12. 8901152 - Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme (2014-12-02),

13. 8889675 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2014-11-18),

14. 8883784 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2014-11-11),

15. 8796289 - Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases (2014-08-05),

Title: Innovations and Contributions of Andrew S Judd in Pharmaceutical Research

Introduction

Andrew S Judd, based in Grayslake, IL, is a prominent inventor with a significant portfolio comprising 21 patents to his name. His work primarily focuses on developing novel therapeutic agents for various diseases, particularly in the field of oncology.

Latest Patents

Among his latest contributions, Judd has been involved in the development of 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 inhibitors. This invention provides compounds that are useful as agents in treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute lymphoblastic leukemia (ALL). Furthermore, he has also disclosed apoptosis-inducing agents that inhibit anti-apoptotic Bcl-xL proteins, showcasing potential in treating cancer and autoimmunity through innovative compositions and therapeutic methods.

Career Highlights

Judd's illustrious career includes valuable contributions to renowned companies such as AbbVie Inc. and Abbott Laboratories Corporation. His expertise in pharmaceutical innovation has led to advancements that significantly impact drug development processes and patient treatments.

Collaborations

Throughout his career, Andrew S Judd has collaborated with notable professionals in the field, including Andrew J Souers and Zhi-Fu Tao. These collaborations have fostered groundbreaking discoveries and technological advancements in pharmaceutical science.

Conclusion

Overall, Andrew S Judd's dedication to innovation and his extensive patent portfolio highlight his critical role in advancing medical treatments. His research not only contributes to scientific knowledge but also aims to improve therapeutic outcomes for patients battling various conditions.

This text is generated by artificial intelligence and may not be accurate.